Schrödinger, Inc. (Nasdaq: SDGR) announced today that initial Phase 1 clinical data for its investigational MALT1 inhibitor, SGR-1505, will be presented at two major international hematology conferences in June 2025. The data will showcase the drug's potential in treating patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The first presentation will take place at the European Hematology Association (EHA) Annual Congress in Milan, Italy (June 12-15, 2025), followed by additional data at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 17-21, 2025).
Phase 1 Study Design and Preliminary Findings
The ongoing Phase 1 study evaluates SGR-1505's safety, tolerability, and anti-tumor activity in patients with relapsed/refractory B-cell malignancies. According to Schrödinger, the upcoming poster presentations will include:
- Initial safety data
- Pharmacokinetic and pharmacodynamic profiles
- Preliminary efficacy results across various dosing levels and schedules
- Data from multiple B-cell malignancy subtypes
The company indicated that current data support the continued development of SGR-1505 in this patient population, suggesting promising early results for this novel therapeutic approach.
Presentation Details
European Hematology Association Annual Congress (EHA)
- Abstract Number: #PS1569
- Poster Title: "A Phase 1 study of SGR-1505, an oral, potent, MALT1 inhibitor for relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL)"
- Presentation: Saturday, June 14, 2025, 6:30-7:30PM CST (12:30-1:30PM ET)
- Location: Poster Session 2
International Conference on Malignant Lymphoma (ICML)
- Abstract Number: #444
- Poster Title: "A Phase 1 study of SGR-1505, an oral, potent MALT1 inhibitor for R/R B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)"
- Presentation: Friday, June 20, 2025, 12:30-13:00PM CST (6:30-7:00AM ET)
- Location: Marquee Parco Ciani
Clinical Significance of MALT1 Inhibition
MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) has emerged as an important therapeutic target in B-cell malignancies. As a key component of the CARD11-BCL10-MALT1 (CBM) signalosome complex, MALT1 plays a crucial role in NF-κB signaling, which is often dysregulated in various B-cell lymphomas.
B-cell malignancies represent a diverse group of hematologic cancers with significant disease burden. Despite advances in treatment options, patients with relapsed or refractory disease face limited therapeutic options and poor prognosis, highlighting the need for novel treatment approaches.
Investor Communication
Schrödinger will host a conference call to review the SGR-1505 Phase 1 data presented at EHA on Thursday, June 12, 2025, at 8:00 a.m. ET. Investors and interested parties can access the live webcast through the "Events & Presentations" section of Schrödinger's website.
The company recommends that participants register at least 15 minutes before the call. The archived webcast will remain available on Schrödinger's website for approximately 90 days following the event.
About Schrödinger and Its Computational Platform
Schrödinger is leveraging its computational platform to transform molecular discovery for drug development and materials design. The company's software platform, built on more than three decades of R&D investment, is licensed by biotechnology, pharmaceutical, and industrial companies, as well as academic institutions worldwide.
Beyond its software offerings, Schrödinger is advancing a portfolio of collaborative and proprietary programs, including three clinical-stage oncology programs. Founded in 1990, the company now employs approximately 900 people across 15 global locations.
Matthew Luchini, Schrödinger's investor contact, emphasized the company's unique approach: "Our computational platform enables the discovery of novel, highly optimized molecules for drug development, as demonstrated by our advancing oncology pipeline."
Future Outlook
While the company remains optimistic about SGR-1505's potential in treating relapsed/refractory B-cell malignancies, Schrödinger acknowledges the inherent uncertainties in drug development. The upcoming data presentations will provide important insights into whether this MALT1 inhibitor could become a valuable addition to the treatment landscape for patients with limited options.
Healthcare professionals and investors alike will be watching closely as these data emerge, potentially signaling a new therapeutic approach for patients with difficult-to-treat blood cancers.
